CN113244387A - 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 - Google Patents

针对降钙素基因相关肽的拮抗剂抗体及其使用方法 Download PDF

Info

Publication number
CN113244387A
CN113244387A CN202110564918.9A CN202110564918A CN113244387A CN 113244387 A CN113244387 A CN 113244387A CN 202110564918 A CN202110564918 A CN 202110564918A CN 113244387 A CN113244387 A CN 113244387A
Authority
CN
China
Prior art keywords
antibody
cgrp
headache
subject
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110564918.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·比加尔
S·沃尔特
H·斯特恩
M·常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54141465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113244387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of CN113244387A publication Critical patent/CN113244387A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CN202110564918.9A 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 Pending CN113244387A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461968897P 2014-03-21 2014-03-21
US61/968,897 2014-03-21
US201462083809P 2014-11-24 2014-11-24
US62/083,809 2014-11-24
US201562119778P 2015-02-23 2015-02-23
US62/119,778 2015-02-23
CN201580025693.2A CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580025693.2A Division CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Publications (1)

Publication Number Publication Date
CN113244387A true CN113244387A (zh) 2021-08-13

Family

ID=54141465

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110564918.9A Pending CN113244387A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN201580025693.2A Pending CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN202010893685.2A Pending CN111973740A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580025693.2A Pending CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN202010893685.2A Pending CN111973740A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Country Status (27)

Country Link
US (3) US9896502B2 (https=)
EP (2) EP4324481A3 (https=)
JP (5) JP6568099B2 (https=)
KR (4) KR20200126018A (https=)
CN (3) CN113244387A (https=)
AU (1) AU2015230933B2 (https=)
BR (1) BR112016021423A2 (https=)
CA (1) CA2943551A1 (https=)
CL (1) CL2016002375A1 (https=)
DK (1) DK3119431T3 (https=)
EA (1) EA201691787A1 (https=)
ES (1) ES2974803T3 (https=)
FI (1) FI3119431T3 (https=)
HR (1) HRP20240159T1 (https=)
HU (1) HUE065397T2 (https=)
IL (2) IL247853B (https=)
LT (1) LT3119431T (https=)
MX (2) MX378344B (https=)
PE (2) PE20161439A1 (https=)
PL (1) PL3119431T3 (https=)
PT (1) PT3119431T (https=)
RS (1) RS65360B1 (https=)
SI (1) SI3119431T1 (https=)
SM (1) SMT202400131T1 (https=)
UA (1) UA123759C2 (https=)
WO (1) WO2015143409A1 (https=)
ZA (1) ZA201606745B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI799849B (zh) 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018055574A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
AU2019246983B2 (en) 2018-04-02 2025-12-18 Amgen Inc. Erenumab compositions and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
CN113227140A (zh) * 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
WO2020163866A1 (en) * 2019-02-08 2020-08-13 Schedule 1 Therapeutics, Inc. Compositions comprising cannabinoids and methods of use thereof
PH12021552422A1 (en) * 2019-05-02 2022-07-11 H Lundbeck As Treatment of headache using anti-cgrp antibodies
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
KR20210124867A (ko) * 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
BR112022024296A2 (pt) * 2020-05-29 2023-04-25 Amgen Inc Formulações de anticorpos e seus usos

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723039A (zh) * 2002-10-08 2006-01-18 里纳特神经系统学公司 通过施用神经生长因子拮抗剂治疗手术后疼痛的方法及包含其的组合物
CN102740884A (zh) * 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
WO2012161956A2 (en) * 2011-05-20 2012-11-29 Alder Biopharmaceuticals, Inc. High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris
CN103143016A (zh) * 2005-04-11 2013-06-12 礼纳特神经系统科学公司 通过给予神经生长因子拮抗剂及其组合物来治疗骨关节炎疼痛的方法
CN103421114A (zh) * 2005-11-14 2013-12-04 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
EP0408294B1 (en) 1989-07-10 1995-09-20 Amylin Pharmaceuticals, Inc. Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994021665A1 (en) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
JPH07196700A (ja) 1994-01-06 1995-08-01 Sando Yakuhin Kk 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP2002511836A (ja) 1996-09-09 2002-04-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
SE9704770D0 (sv) 1997-12-19 1997-12-19 Astra Ab New use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
US6552043B1 (en) 1998-09-30 2003-04-22 Merck Sharpe & Dohme Ltd. Benzimidazolinyl piperidines as CGRP ligands
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
EP1158997A2 (en) 1999-03-09 2001-12-05 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7097467B2 (en) 2002-06-03 2006-08-29 Wan-Tien Chen Dustproof plate fixture for an electrical connector
BRPI0311812B8 (pt) 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
CA2495498C (en) 2002-08-12 2014-04-15 Birkir Sveinsson Use of cgrp antagonist compounds for treatment of psoriasis
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
CA2519475A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
CA2518830A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Carboxamide spirohydantoin cgrp receptor antagonists
JP4673296B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション アリールスピロヒダントインｃｇｒｐ受容体拮抗物質
AU2004221891B2 (en) 2003-03-14 2009-11-19 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin CGRP receptor antagonists
JP4705908B2 (ja) 2003-04-15 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
WO2005041757A2 (en) 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP2007533685A (ja) 2004-04-20 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたｃｇｒｐアンタゴニストの使用
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2007025212A2 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
JP2009508970A (ja) 2005-09-21 2009-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 疼痛の局所造影および治療のためのシステム、組成物並びに方法
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
JP5511379B2 (ja) 2006-07-21 2014-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｇｒｐレセプターアンタゴニスト
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
CA2703364A1 (en) 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
DK2265288T3 (en) 2008-03-04 2016-06-06 Labrys Biologics Inc Methods for the treatment of inflammatory pain
CA2716424C (en) * 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
AU2009240419A1 (en) 2008-04-25 2009-10-29 Nellix, Inc. Stent graft delivery system
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TWI685505B (zh) 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EP2744903B1 (en) 2011-08-19 2018-10-10 AlderBio Holdings LLC Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as a antibodies in transformed microbes such as pichia pastoris
EP2802659A1 (en) 2012-01-10 2014-11-19 Noxxon Pharma AG Nucleic acids specifically binding cgrp
US8722060B2 (en) 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
US10249132B2 (en) 2012-10-29 2019-04-02 Netent Product Services Ltd. Architecture for multi-player, multi-game, multi-table, multi-operator and multi-jurisdiction live casino gaming
EP2972330A4 (en) 2013-03-15 2016-10-26 Alder Biopharmaceuticals Inc PROTOCOL FOR THE IDENTIFICATION AND ISOLATION OF ANTIGEN-SPECIFIC B-CELLS AND FOR THE PREPARATION OF ANTIBODIES FOR DESIRED ANTIGENES
CA2905180C (en) 2013-03-15 2023-03-07 Alder Biopharmaceuticals, Inc. Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
SG10201906172XA (en) 2013-07-03 2019-08-27 Alder Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI799849B (zh) 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EA201890578A1 (ru) 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CA3037661A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
JP2021534197A (ja) 2018-08-22 2021-12-09 イーライ リリー アンド カンパニー 治療抵抗性患者のための抗ｃｇｒｐ抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723039A (zh) * 2002-10-08 2006-01-18 里纳特神经系统学公司 通过施用神经生长因子拮抗剂治疗手术后疼痛的方法及包含其的组合物
CN103143016A (zh) * 2005-04-11 2013-06-12 礼纳特神经系统科学公司 通过给予神经生长因子拮抗剂及其组合物来治疗骨关节炎疼痛的方法
CN103421114A (zh) * 2005-11-14 2013-12-04 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN102740884A (zh) * 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
WO2012161956A2 (en) * 2011-05-20 2012-11-29 Alder Biopharmaceuticals, Inc. High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris

Also Published As

Publication number Publication date
US20190031745A1 (en) 2019-01-31
EA201691787A1 (ru) 2017-02-28
US9896502B2 (en) 2018-02-20
IL294490A (en) 2022-09-01
UA123759C2 (uk) 2021-06-02
KR102274964B1 (ko) 2021-07-09
JP2024040245A (ja) 2024-03-25
AU2015230933B2 (en) 2020-08-13
NZ761478A (en) 2024-01-26
LT3119431T (lt) 2024-03-12
ES2974803T3 (es) 2024-07-01
JP2019123750A (ja) 2019-07-25
JP2021014464A (ja) 2021-02-12
MX378344B (es) 2025-03-10
CL2016002375A1 (es) 2017-05-19
KR20220130822A (ko) 2022-09-27
RS65360B1 (sr) 2024-04-30
AU2015230933A1 (en) 2016-11-03
SI3119431T1 (sl) 2024-06-28
CA2943551A1 (en) 2015-09-24
US20150266948A1 (en) 2015-09-24
KR20240146107A (ko) 2024-10-07
PT3119431T (pt) 2024-04-16
WO2015143409A1 (en) 2015-09-24
FI3119431T3 (fi) 2024-03-20
PE20161439A1 (es) 2017-01-26
CN111973740A (zh) 2020-11-24
HRP20240159T1 (hr) 2024-04-12
US11555064B2 (en) 2023-01-17
US20200331991A1 (en) 2020-10-22
MX2020012816A (es) 2021-02-15
JP2021121637A (ja) 2021-08-26
EP3119431A4 (en) 2017-09-06
EP3119431B1 (en) 2024-01-24
NZ724442A (en) 2021-02-26
HK1232129A1 (en) 2018-01-05
HUE065397T2 (hu) 2024-06-28
SMT202400131T1 (it) 2024-05-14
ZA201606745B (en) 2022-12-21
KR20200126018A (ko) 2020-11-05
IL247853A0 (en) 2016-11-30
EP4324481A3 (en) 2024-05-01
KR20160147755A (ko) 2016-12-23
DK3119431T3 (da) 2024-03-18
JP6568099B2 (ja) 2019-08-28
PL3119431T3 (pl) 2024-06-24
BR112016021423A2 (pt) 2017-11-14
CN106456759A (zh) 2017-02-22
JP2017510579A (ja) 2017-04-13
PE20220337A1 (es) 2022-03-14
MX2016012188A (es) 2017-04-27
US10519224B2 (en) 2019-12-31
IL247853B (en) 2022-08-01
EP4324481A2 (en) 2024-02-21
EP3119431A1 (en) 2017-01-25
JP6892891B2 (ja) 2021-06-23

Similar Documents

Publication Publication Date Title
US11555064B2 (en) Treating headache comprising administering an antibody to calcitonin gene-related peptide
US20230235032A1 (en) Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
CN101309704B (zh) 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
HK1225627A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide for treating cluster headache
HK1258385A1 (zh) 预防、治疗和减轻(持续性)创伤後头痛
HK40041381A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1233955A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
BR122020017648B1 (pt) Composição para o tratamento ou redução da incidência de enxaqueca compreendendo um anticorpo monoclonal que inibe a via do peptídeo relacionado ao gene da calcitonina
HK40051844A (en) Antagonist antibodies directed against calcitonin gene-related peptide
HK1227724A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1227724A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1125837B (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1190411A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
NZ724442B2 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1232129B (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination